Category Regional Policy

US Congressional Watchdog Launches Team For Sci/Tech Analysis

A new chapter begins. The business of technology and science has been, and will increasingly be, the business of government: with this in mind, the US Government Accountability Office (GAO) has launched a new Science, Technology Assessment and Analytics (STTA) team with the aim to expand the support to lawmakers on topics whose importance has exponentially increased in the world of today.

DNDi, MMV Make 400 Compounds Available To Boost Pandemic Disease Research

The Drugs for Neglected Diseases initiative (DNDi) and Medicines for Malaria Venture (MMV) today announced the launch of the "Pandemic Response Box", which offers researchers open access to 400 compounds that could lead to development of new treatments for pandemic diseases. In return, researchers "will be expected to share data resulting from research on the molecules from the box in the public domain within 2 years of its generation." 

Open Access Advocates See End Of US Copyright Term Extension Act As Win For Commons

Open access advocates in the United States are celebrating the expiration, and non-renewal, of the Copyright Term Extension Act, which introduces into the public domain all works from 1923, and signals an end of the practice by US lawmakers to continually extend the terms of copyright protection.

Leading figures from groups such as Creative Commons and Wikimedia Foundation gathered to discuss why this shift in policy took place, and what it means for the public domain. They asserted that this change is the result of a general acceptance of the value of “the commons,” brought on in part by the era of the internet.

US Complaints About Technology Transfer In China: Negotiating The Endgame

Dean Pinkert writes: The United States Trade Representative (USTR) has been open about its view of the difficulties faced by US companies who claim – generally anonymously – that they have been forced to transfer technology to Chinese entities: “The fact that China systematically implements its technology transfer regime in informal and indirect ways makes it ‘just as effective [as written requirements], but almost impossible to prosecute.’” As I explain in this article, I believe such informality is not merely a barrier to prosecutions; it also presents conceptual challenges for US trade negotiators as they attempt to craft effective means to address the concerns of US companies doing business in China.

Sudden Vacancies At Some International Agencies, Industry Sees New Top Officials, Lawyers Engage In Firm-Hopping

While the World Bank Group and the United Nations Environment Programme (UNEP) are looking for new leaders following the unexpected resignations of their heads, the International Telecommunication Union re-elected its secretary general. The European Patent Office got two new vice-chairs, and the European Organization for Nuclear Research (CERN) a new president, both starting in January. Associations for the creative industry and the pharmaceutical industry also elected new top officials, and lawyers continued to practice firm-hopping.

Nearly 100 European Authors Demand ‘Proportionate’ Remuneration In EU Copyright Directive

With negotiations for the European Union Copyright Directive apparently approaching an end, a group of some 95 screenwriters and directors joined the intensive lobbying efforts with a letter today urging that a principle of "proportionate" remuneration to them be enshrined. The letter spells out several elements they argue are key to ensuring European audiovisual authors are able to "make a living from our craft and creativity."

European Council Advances SPC Waiver For Generics; Negotiations Coming

The European Union Council of member states has approved a mandate for negotiations with the EU Parliament concerning a draft regulation aimed at boosting EU-based generic and biosimilar manufacturing for export by providing an exception to the extended intellectual property protection granted by special protection certificates (SPCs). The mandate brings the draft regulation a step closer to adoption, and it also suggests that Parliament’s recent amendments to the regulation are likely be key areas of debate in the negotiations, which are expected to begin in the coming weeks.

Supporting UHC And Better Explaining IP – The 2019 Pharma Industry Agenda

In 2019, IFPMA work will continue to focus on constructive engagement in supporting UHC and working with others to strengthen health care systems. The association will continue to engage with a range of stakeholders, particularly multilateral organizations, to better explain the benefits of IP and exchange ideas to address issues of coverage, capacity, affordability and sustainability of healthcare.